|
US5304121A
(en)
|
1990-12-28 |
1994-04-19 |
Boston Scientific Corporation |
Drug delivery system making use of a hydrogel polymer coating
|
|
US5994341A
(en)
|
1993-07-19 |
1999-11-30 |
Angiogenesis Technologies, Inc. |
Anti-angiogenic Compositions and methods for the treatment of arthritis
|
|
US6099562A
(en)
|
1996-06-13 |
2000-08-08 |
Schneider (Usa) Inc. |
Drug coating with topcoat
|
|
KR20050044450A
(ko)
|
2001-11-14 |
2005-05-12 |
테바 파마슈티컬 인더스트리즈 리미티드 |
로사르탄 칼륨의 무정형 및 결정형 형태 및 이의 제조 방법
|
|
WO2006011050A2
(en)
|
2004-07-23 |
2006-02-02 |
Pfizer Limited |
Pyridine derivatives
|
|
EP2073806B1
(en)
|
2006-10-12 |
2012-02-15 |
Xenon Pharmaceuticals Inc. |
Use of spiro-oxindole compounds as therapeutic agents
|
|
EA015952B1
(ru)
|
2007-05-03 |
2011-12-30 |
Пфайзер Лимитед |
2-пиридинкарбоксамидные производные в качестве модуляторов натриевых каналов
|
|
MX2011006904A
(es)
|
2008-12-26 |
2011-07-20 |
Dainippon Sumitomo Pharma Co |
Compuesto heterociclico biciclico novedoso.
|
|
CA2760946C
(en)
|
2009-05-07 |
2019-06-25 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for studying, imaging, and treating pain
|
|
AR077252A1
(es)
|
2009-06-29 |
2011-08-10 |
Xenon Pharmaceuticals Inc |
Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
|
|
CA2771472A1
(en)
|
2009-09-04 |
2011-03-10 |
Zalicus Pharmaceuticals Ltd. |
Oxopiperazine derivatives for the treatment of pain and epilepsy
|
|
US8598164B2
(en)
|
2010-05-06 |
2013-12-03 |
Vertex Pharmaceuticals Incorporated |
Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels
|
|
KR101923367B1
(ko)
|
2011-02-02 |
2018-12-04 |
버텍스 파마슈티칼스 인코포레이티드 |
이온 채널의 조절제로서의 피롤로피라진―스피로사이클릭 피페리딘 아미드
|
|
WO2012112743A1
(en)
|
2011-02-18 |
2012-08-23 |
Vertex Pharmaceuticals Incorporated |
Chroman - spirocyclic piperidine amides as modulators of ion channels
|
|
CA2828456C
(en)
|
2011-03-03 |
2021-05-04 |
Zalicus Pharmaceuticals Ltd. |
N-benzl-amino-carboxamide inhibitors of the sodium channel
|
|
US8828996B2
(en)
|
2011-03-14 |
2014-09-09 |
Vertex Pharmaceuticals Incorporated |
Morpholine-spirocyclic piperidine amides as modulators of ion channels
|
|
BR112014009102A2
(pt)
|
2011-10-26 |
2017-04-18 |
Pfizer Ltd |
compostos químicos
|
|
WO2013086229A1
(en)
|
2011-12-07 |
2013-06-13 |
Amgen Inc. |
Bicyclic aryl and heteroaryl sodium channel inhibitors
|
|
WO2013109521A1
(en)
|
2012-01-16 |
2013-07-25 |
Vertex Pharmaceuticals Incorporated |
Pyran-spirocyclic piperidine amides as modulators of ion channels
|
|
WO2013114250A1
(en)
|
2012-02-03 |
2013-08-08 |
Pfizer Inc. |
Benziimidazole and imidazopyridine derivatives as sodium channel modulators
|
|
WO2013131018A1
(en)
|
2012-03-02 |
2013-09-06 |
Zalicus Pharmaceuticals Ltd. |
Biaryl inhibitors of the sodium channel
|
|
US9051311B2
(en)
|
2012-03-09 |
2015-06-09 |
Amgen Inc. |
Sulfamide sodium channel inhibitors
|
|
US20140211173A1
(en)
|
2013-01-30 |
2014-07-31 |
3M Innovative Properties Company |
Optical projection subsystem
|
|
KR102226587B1
(ko)
|
2013-01-31 |
2021-03-11 |
버텍스 파마슈티칼스 인코포레이티드 |
나트륨 채널의 조절제로서의 퀴놀린 및 퀴나졸린 아미드
|
|
CN105026373B
(zh)
|
2013-01-31 |
2018-03-30 |
沃泰克斯药物股份有限公司 |
作为钠通道调节剂的吡啶酮酰胺
|
|
BR112015018284B1
(pt)
|
2013-01-31 |
2023-03-07 |
Vertex Pharmaceuticals Incorporated |
Amidas como moduladores de canais de sódio, seus usos, e composição farmacêutica
|
|
US9212182B2
(en)
|
2013-06-12 |
2015-12-15 |
Amgen Inc. |
Bicyclic sulfonamide compounds as sodium channel inhibitors
|
|
JP6337109B2
(ja)
|
2013-07-19 |
2018-06-06 |
バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ |
ナトリウムチャネルの調節剤としてのスルホンアミド
|
|
SG11201604477SA
(en)
|
2013-12-13 |
2016-07-28 |
Vertex Pharma |
Prodrugs of pyridone amides useful as modulators of sodium channels
|
|
CA2944549A1
(en)
|
2014-04-09 |
2015-10-15 |
Siteone Therapeutics, Inc. |
10',11'-modified saxitoxin useful for the treatment of pain
|
|
AU2016226340B2
(en)
|
2015-03-02 |
2019-11-07 |
Amgen Inc. |
Bicyclic ketone sulfonamide compounds
|
|
AU2016329201A1
(en)
|
2015-09-30 |
2018-04-26 |
Siteone Therapeutics, Inc. |
11,13-modified saxitoxins for the treatment of pain
|
|
CA3058214A1
(en)
|
2017-03-29 |
2018-10-04 |
The Board Of Trustees Of The Leland Stanford Junior University |
11,13-modified saxitoxins for the treatment of pain
|
|
JP2020515611A
(ja)
|
2017-03-29 |
2020-05-28 |
サイトワン セラピューティクス， インコーポレイテッド |
疼痛の処置のための１１，１３−修飾サキシトキシン
|
|
KR102714561B1
(ko)
|
2017-05-16 |
2024-10-10 |
버텍스 파마슈티칼스 인코포레이티드 |
나트륨 채널의 조절제로서의 중수소화 피리돈 아미드 및 이의 프로드럭
|
|
AU2018300150A1
(en)
|
2017-07-11 |
2020-01-30 |
Vertex Pharmaceuticals Incorporated |
Carboxamides as modulators of sodium channels
|
|
AU2019302534B2
(en)
|
2018-07-09 |
2024-10-03 |
Lieber Institute, Inc. |
Pyridazine compounds for inhibiting NaV1.8
|
|
SG11202100130QA
(en)
|
2018-07-09 |
2021-02-25 |
Lieber Institute Inc |
Pyridine carboxamide compounds for inhibiting nav1.8
|
|
EP3860714B1
(en)
|
2018-10-03 |
2023-09-06 |
Siteone Therapeutics, Inc. |
11,13-modified saxitoxins for the treatment of pain
|
|
GEAP202315648A
(en)
|
2018-11-02 |
2023-07-25 |
Merck Sharp & Dohme Llc |
2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors
|
|
WO2020092187A1
(en)
|
2018-11-02 |
2020-05-07 |
Merck Sharp & Dohme Corp. |
2-amino-n-phenyl-nicotinamides as nav1.8 inhibitors
|
|
WO2020117626A1
(en)
|
2018-12-05 |
2020-06-11 |
Merck Sharp & Dohme Corp. |
4-amino or 4-alkoxy-substituted aryl sulfonamide compounds with selective activity in voltage-gated sodium channels
|
|
WO2020140959A1
(zh)
|
2019-01-04 |
2020-07-09 |
江苏恒瑞医药股份有限公司 |
6-氧代-1,6-二氢哒嗪类衍生物、其制备方法及其在医药上的应用
|
|
WO2020146682A1
(en)
|
2019-01-10 |
2020-07-16 |
Vertex Pharmaceuticals Incorporated |
Carboxamides as modulators of sodium channels
|
|
WO2020146612A1
(en)
|
2019-01-10 |
2020-07-16 |
Vertex Pharmaceuticals Incorporated |
Esters and carbamates as modulators of sodium channels
|
|
WO2020151728A1
(zh)
|
2019-01-25 |
2020-07-30 |
江苏恒瑞医药股份有限公司 |
2-氧代-1,2-二氢吡啶类衍生物、其制备方法及其在医药上的应用
|
|
MA56398A
(fr)
|
2019-06-27 |
2022-05-04 |
Glaxosmithkline Ip Dev Ltd |
Composés 2,3-dihydroquinazoline en tant qu'inhibiteurs de nav1.8
|
|
CN112300051A
(zh)
|
2019-07-31 |
2021-02-02 |
明慧医药（上海）有限公司 |
一种选择性钠通道调节剂及其制备和应用
|
|
CN112300069A
(zh)
|
2019-07-31 |
2021-02-02 |
明慧医药（上海）有限公司 |
一种选择性钠通道调节剂及其制备和应用
|
|
CN112390745B
(zh)
|
2019-08-19 |
2022-10-21 |
江苏恒瑞医药股份有限公司 |
吡啶烟酰胺类衍生物、其制备方法及其在医药上的应用
|
|
TW202115038A
(zh)
|
2019-08-19 |
2021-04-16 |
大陸商江蘇恆瑞醫藥股份有限公司 |
苯甲醯胺稠芳環類衍生物、其製備方法及其在醫藥上的應用
|
|
CN112441969A
(zh)
|
2019-08-30 |
2021-03-05 |
明慧医药（上海）有限公司 |
一种选择性钠通道调节剂及其制备和应用
|
|
KR20220101606A
(ko)
|
2019-09-12 |
2022-07-19 |
상하이 제민케어 파마슈티칼스 컴퍼니 리미티드 |
피리딘 산질화물 및 이의 제조 방법과 용도
|
|
PH12022551379A1
(en)
|
2019-12-06 |
2023-05-03 |
Vertex Pharma |
Substituted tetrahydrofurans as modulators of sodium channels
|
|
CN111217776A
(zh)
|
2020-01-19 |
2020-06-02 |
中国人民解放军军事科学院军事医学研究院 |
含苯并杂环结构的酰胺衍生物、组合物和应用
|
|
JP7739051B2
(ja)
|
2020-06-10 |
2025-09-16 |
アムジエン・インコーポレーテツド |
シクロブチルジヒドロキノリンスルホンアミド化合物
|
|
JP7879815B2
(ja)
|
2020-06-10 |
2026-06-24 |
アムジエン・インコーポレーテツド |
ヘテロアルキルジヒドロキノリンスルホンアミド化合物
|
|
JP7880201B2
(ja)
|
2020-06-10 |
2026-06-25 |
アムジエン・インコーポレーテツド |
シクロプロピルジヒドロキノリンスルホンアミド化合物
|
|
KR20230026404A
(ko)
|
2020-06-17 |
2023-02-24 |
머크 샤프 앤드 돔 엘엘씨 |
Nav1.8 억제제로서의 2-옥소-옥사졸리딘-5-카르복스아미드
|
|
US11802122B2
(en)
|
2020-06-17 |
2023-10-31 |
Merck Sharp & Dohme Llc |
2-oxoimidazolidine-4-carboxamides as NAv1.8 inhibitors
|
|
CN115697327A
(zh)
|
2020-06-17 |
2023-02-03 |
默沙东有限责任公司 |
作为nav1.8抑制剂的5-氧代-吡咯烷-3-甲酰胺
|
|
EP4196482B1
(en)
|
2020-08-14 |
2025-10-01 |
SiteOne Therapeutics, Inc. |
Non-hydrated ketone inhibitors of nav1.7 for the treatment of pain
|
|
TW202214259A
(zh)
|
2020-08-19 |
2022-04-16 |
大陸商江蘇恆瑞醫藥股份有限公司 |
一種選擇性ＮａＶ抑制劑的前藥及其晶型
|
|
TW202220962A
(zh)
|
2020-08-19 |
2022-06-01 |
大陸商江蘇恒瑞醫藥股份有限公司 |
選擇性NaV抑制劑的結晶形式及其製備方法
|
|
CN111808019B
(zh)
|
2020-09-08 |
2020-11-27 |
上海济煜医药科技有限公司 |
一种并环化合物及其应用
|
|
CN112225695B
(zh)
|
2020-12-15 |
2021-03-02 |
上海济煜医药科技有限公司 |
一种氮氧化合物及其制备方法和用途
|
|
CN112457294B
(zh)
|
2021-01-27 |
2021-06-04 |
上海济煜医药科技有限公司 |
一种作为NaV1.8阻滞剂的化合物及其制备方法和用途
|
|
US20240368135A1
(en)
*
|
2021-06-04 |
2024-11-07 |
Vertex Pharmaceuticals Incorporated |
Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels
|